
    
      CONSOLIDATION: Patients receive bortezomib, lenalidomide, and dexamethasone (VLD) therapy
      comprising bortezomib intravenously (IV) on days 1, 4, 8, and 11, lenalidomide orally (PO)
      once daily (QD) on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and
      12. Courses continue for 28 days and repeat every 3 months in the absence of disease
      progression or unacceptable toxicity.

      In between courses of VLD, patients receive Lenalidomide + Dexamethasone (LD) therapy
      comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3).
      Courses continue for 28 days.

      MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on
      days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in
      the absence of disease progression or unacceptable toxicity.
    
  